“…[4][5][6][7][8][9] However, there are few reports on the patency rate of forearm BVT (FBVT). [10][11][12] Although only 10 cases were included in a retrospective study, Gormus et al 10 reported a 90% patency rate for FBVT at 10 months and 80% for UBVT. Weyde et al 11 reported patency rates of FBVT as 70.4% at 1 year and 48.4% at 3 years.…”
Section: Discussionmentioning
confidence: 99%
“…[10][11][12] We thought that forearm basilic vein could be used as an alternative for UBVT, providing another option for autogenous hemodialysis access. It could be used in patients with failed direct AVFs (DAVFs), such as radial-cephalic direct wrist access or brachialcephalic upper arm direct access.…”
Forearm BVT showed an acceptable, high 2-year patency rate and fewer thromboses and infectious complications than AVG. Forearm BVT could be considered before forming an upper arm AVF or forearm AVG, if the basilic vein is available.
“…[4][5][6][7][8][9] However, there are few reports on the patency rate of forearm BVT (FBVT). [10][11][12] Although only 10 cases were included in a retrospective study, Gormus et al 10 reported a 90% patency rate for FBVT at 10 months and 80% for UBVT. Weyde et al 11 reported patency rates of FBVT as 70.4% at 1 year and 48.4% at 3 years.…”
Section: Discussionmentioning
confidence: 99%
“…[10][11][12] We thought that forearm basilic vein could be used as an alternative for UBVT, providing another option for autogenous hemodialysis access. It could be used in patients with failed direct AVFs (DAVFs), such as radial-cephalic direct wrist access or brachialcephalic upper arm direct access.…”
Forearm BVT showed an acceptable, high 2-year patency rate and fewer thromboses and infectious complications than AVG. Forearm BVT could be considered before forming an upper arm AVF or forearm AVG, if the basilic vein is available.
“…Since that time, multiple studies have reported a wide range of long-term patency results for BVT (4,6,(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24). Gormus et al (25) have shown no significant differences between forearm and upper arm BVT. Literature regarding CVT is sparse (17).…”
“…With maturation failure and thrombosis combined, there is little difference in fistula patency between brachiocephalic and transposed brachiobasilic vein fistulas (8), suggesting the possibility of earlier thrombosis with brachiocephalic fistulas. Radiobasilic fistulas also have similar patency to brachiobasilic fistulas, although early thrombosis may also occur with slightly more frequency, but can be treated with secondary intervention (19). Assisted patency of transposed brachiobasilic vein fistulas is reported to be approximately 64–66% at 1 year, 53–58% at 2 years, and 43% at 3 years (20–22).…”
Section: Native Fistula Placement: the First Prophylaxis Against Thromentioning
Vascular access thrombosis in the hemodialysis patient leads to significant cost and morbidity. Fistula patency supersedes graft patency, therefore obtaining a mature functioning fistula in patients approaching end-stage renal disease (ESRD) by early patient education and referral needs to be practiced. Current methods to maintain vascular access patency rely on early detection and radiologic or surgical prevention of thrombosis. Study of thrombosis biology has elucidated other potential targets for the prophylaxis of vascular access thrombosis. The goal of this review is to examine the current available methods for vascular access thrombosis prophylaxis.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.